Description
This 3D mechanism-of-action animation has been created for the U.S. product launch of Abstral® (fentanyl) Sublingual Tablets, the treatment for Breakthrough Cancer Pain (BTcP).
We began the video with the introduction of the cause of pain; highlighting metastatic bone cancer, before showcasing the mechanism of action (MOA) of the drug and its significant effect on breakthrough cancer pain.
Deliverables
3D animation, product shots, high resolution images
Brand
Abstral®
Client
Galena Biopharma
Galena Biopharma
Oregon, USA
What is Breakthrough Cancer Pain
1Breakthrough cancer pain (BTcP) is defined as a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.
Breakthrough cancer pain occurs in the majority of patients who are already receiving chronic, long-acting opioid pain management and yet have episodes of severe tumor- and treatment-related cancer pain.
reference: 1galenabiopharma.com